Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.27
Dollar change
+0.03
Percentage change
1.34
%
IndexRUT P/E- EPS (ttm)-3.70 Insider Own53.42% Shs Outstand40.36M Perf Week-9.56%
Market Cap91.62M Forward P/E- EPS next Y-2.13 Insider Trans0.00% Shs Float18.80M Perf Month-10.98%
Income-73.50M PEG- EPS next Q-0.55 Inst Own18.26% Short Float8.25% Perf Quarter-26.30%
Sales10.63M P/S8.62 EPS this Y-26.12% Inst Trans-32.96% Short Ratio10.60 Perf Half Y-50.06%
Book/sh1.15 P/B1.98 EPS next Y15.46% ROA-47.96% Short Interest1.55M Perf Year-23.83%
Cash/sh2.33 P/C0.97 EPS next 5Y- ROE-69.56% 52W Range1.96 - 9.77 Perf YTD-22.53%
Dividend Est.- P/FCF- EPS past 5Y38.31% ROI-154.22% 52W High-76.76% Beta0.99
Dividend TTM- Quick Ratio7.53 Sales past 5Y46.73% Gross Margin80.10% 52W Low15.82% ATR (14)0.19
Dividend Ex-Date- Current Ratio7.53 EPS Y/Y TTM-958.84% Oper. Margin-699.16% RSI (14)44.21 Volatility8.16% 8.35%
Employees17 Debt/Eq0.06 Sales Y/Y TTM-82.28% Profit Margin-691.39% Recom1.40 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.03 EPS Q/Q-126.11% Payout- Rel Volume1.24 Prev Close2.24
Sales Surprise222.49% EPS Surprise7.02% Sales Q/Q-90.43% EarningsNov 09 BMO Avg Volume146.45K Price2.27
SMA20-7.42% SMA50-3.22% SMA200-46.07% Trades Volume181,557 Change1.34%
Date Action Analyst Rating Change Price Target Change
Oct-03-23Initiated CapitalOne Overweight $10
Jul-06-23Initiated Evercore ISI Outperform $12
May-31-23Upgrade Jefferies Hold → Buy $0.60 → $7
May-24-23Initiated H.C. Wainwright Buy $10
Apr-14-23Initiated Robert W. Baird Outperform $10
Mar-21-24 05:00PM
Feb-28-24 07:30AM
Dec-21-23 07:00AM
Dec-14-23 07:00AM
Nov-28-23 07:00AM
07:30AM Loading…
Nov-22-23 07:30AM
Nov-09-23 07:30AM
Oct-31-23 09:25AM
Oct-25-23 09:11AM
Oct-12-23 02:52PM
Sep-05-23 08:30AM
Sep-01-23 08:30AM
Aug-24-23 08:30AM
Aug-23-23 09:55AM
Aug-13-23 08:07AM
07:30AM Loading…
Aug-10-23 07:30AM
Jul-19-23 06:34AM
Jun-28-23 08:30AM
Jun-26-23 08:30AM
Jun-14-23 08:30AM
Jun-08-23 01:11PM
Jun-05-23 07:30AM
May-30-23 04:30PM
May-11-23 07:30AM
May-08-23 04:30PM
May-05-23 04:30PM
Apr-14-23 12:51PM
Apr-06-23 04:30PM
Apr-04-23 08:30AM
Mar-20-23 02:04PM
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.